Merck (14+ billion in cash) seems to be targeting both LILRB2 and TREM2. So there’s definitely enough at stake. Results can be expected from those, at least.
Might even be interested in BEX!
4 Likes
Merck (14+ billion in cash) seems to be targeting both LILRB2 and TREM2. So there’s definitely enough at stake. Results can be expected from those, at least.
Might even be interested in BEX!